Infectious Disease Therapeutics Market Analysis By Disease Type (HIV infection, Influenza, Malaria, Tuberculosis, Hepatitis, and HPV infection), By Region, And Segment Forecasts, 2018 - 2025

Industry Insights

The global infectious disease therapeutics market size was valued at USD 46.88 billion in 2016 and is projected to grow at a CAGR of 6.6% during the forecast period. Rising prevalence of infectious ailments, increasing expenditure to boost the penetration rate of treatments of these diseases, rising initiatives for creating awareness about treatments & diagnosis of these conditions, and increasing clinical trial studies for the development of new drugs are likely to be the factors responsible for the growth of this market.

Also, the market is likely to witness the patent expiration of many drugs during the forecast period. The expiry of patents results in the availability of generic drugs, which have the same drug constitution as branded drugs but are available at a very low price. Also, physicians prescribe these drugs to patients as they are cost-effective. Furthermore, a positive reimbursement scenario that covers the diagnosis and treatments of these disorders is expected to propel the market growth.

However, lack of awareness about treatments for these disorders and low adoption of treatments are factors expected to restraint the growth in the coming years. Africa and Asia have a high incidence of infectious disorders and a low penetration rate of treatments for the same. According to AVERT, in 2015, 6.5 million individuals were infected with Human Immunodeficiency Virus (HIV) in the West and Central African region and 28% of the HIV infected people were accessing antiretroviral therapy. Furthermore, increasing the availability of counterfeit drugs in Asian countries is expected to pose a significant threat to the market during the forecast period.

Key players are developing new products for the treatment of infectious diseases and are also receiving approvals to commercialize their products. For instance, in May 2017, Merck received FDA approval for its ISENTRESS HD, a new 1200 mg integrase inhibitor for HIV-1 infected patients. This drug can also be used in combination therapy with other antiretrovirals. Furthermore, in January 2017, BioCryst received Health Canada approval for its drug RAPIVAB for treating patients infected with influenza.

Disease Type Insights

Based on disease types, the market is segmented into HIV, malaria, hepatitis, influenza, Human Papillomavirus (HPV), and tuberculosis. In 2016, the HIV segment held the largest share i.e., 45.9% of the market. Increasing prevalence of HIV, rising funding activities for patients suffering from HIV, increasing supply of free HIV self-test kits in African countries, and raising awareness campaigns are the key factors responsible for the largest share held by this segment.

In 2016, hepatitis therapeutics segment held the second-largest share in the top six infectious disease therapeutics market. Rising prevalence of hepatitis, increasing clinical trial activities for the launch of new drugs, and a growing number of initiatives to increase the adoption of drugs are expected to be the factors responsible for the second-largest share held by this segment. Also, WHO aims to test 90% and treat 80% of the people suffering from HBV and HCV by 2030, through its Global Health Sector Strategy on viral hepatitis, which is further expected to contribute to the growth of this segment.

The HPV segment is estimated to grow at the highest rate during the forecast period. Major factors that are responsible for its growth include the increasing prevalence of HPV and the low cost of drugs that are used in the treatment of this infection. According to WHO, HPV is the most common sexually transmitted infection and the majority of the sexually active individuals are likely to be infected with this virus at least once in their lifetime. HPV infection does not have any treatment. However, the symptoms of HPV such as genital warts can be treated using various anti-infective drugs.

Regional Insights

North America dominated the market in 2016 with a revenue share of around 38.6%. Increasing prevalence of such disorders and favorable reimbursement scenario are key factors likely to propel the demand for infectious disease therapeutics in the region. Furthermore, the presence of a large number of manufacturers in the U.S. and increasing numbers of clinical trials for the development of new treatment drugs are expected to contribute to the large market share held by this region. Major factors that are likely to propel the growth of this market include the increasing rate of treatment & diagnosis of infectious diseases and rising funding activities to support the development of new drugs.

Asia Pacific is estimated to grow at the fastest CAGR during the forecast period. High prevalence of HIV, malaria, TB, and other infections; increasing incidence of these conditions; and rising expenditure on the prevention and diagnosis of infectious diseases are likely to be the key factors responsible for the growth of this market. Furthermore, increasing the focus of governments of various countries on the prevention of infections and on raising funds to increase the adoption of treatments for infectious diseases are expected to further propel the market during the forecast period.

The majority of the people suffering from these infections are living in Africa. According to WHO, in 2015, 90% of malaria deaths occurred in the African region. Various initiatives focusing on disease prevention are being undertaken in the region. Furthermore, government, private, and nonprofit organizations are focusing on increasing the management of these diseases. For instance, Novartis supplies free drugs to patients suffering from malaria in the African region.

Competitive Insights

Some of the significant players operating in this market are Novartis AG, Gilead, GlaxoSmithKline plc, Janssen Pharmaceutical, Inc., F. Hoffmann-La Roche Ltd., BioCryst Pharmaceuticals, Inc., Merck & Co., Inc., and Boehringer Ingelheim GmbH. Incessant regulatory approval for commercial availability of anti-infective is likely to be the key factor attributing to the share of these players in the top six infectious disease therapeutics market.

Report Scope

Attribute	Details
The base year for estimation	2016
Actual estimates/Historic data	2014 - 2015
Forecast period	2017 - 2025
Market representation	Revenue in USD Million & CAGR from 2017 to 2025
Regional scope	North America, Europe, Asia Pacific, Latin America, MEA
Country scope	U.S., Canada, Germany, UK, Japan, China, Brazil, Mexico, South Africa
Report coverage	Top 6 Infectious Disease Therapeutics, Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)	如果你需要特定的市场信息,这是not currently within the scope of the report, we will provide it to you as a part of customization

赛格ments Covered in the Report

This report forecasts revenue growth and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For this study, Grand View Research has segmented the infectious disease therapeutics market based on disease type and region:

• Disease Type Outlook (Revenue, USD Million; 2014 - 2025)

  • HIV

    • Emtriva

    • Aptivus

    • Isentress

    • Lexiva/Telzir

    • Selzentry

    • Tivicay

    • Atripla

    • Complera

    • Genvoya

    • Odefsey

    • Stribild

    • Truvada

    • Triumeq

    • Descovy

    • Vitekta

    • Others

  • Influenza

    • Relenza

    • Tamiflu

    • Rapivab

    • Others

  • TB

    • Sirturo

    • Others

  • Malaria

    • Coartem

    • Others

  • Hepatitis

  • HPV

• Regional Outlook (Revenue, USD Million; 2014 - 2025)

  • North America

    • The U.S.

    • Canada

  • Europe

    • Germany

    • UK

  • Asia Pacific

    • Japan

    • China

  • Latin America

    • Brazil

    • Mexico

  • MEA

    • South Africa